Sign Up to like & get recommendations! 0
Published in 2019 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2019.4534
Abstract: Importance It is unclear whether hypertrophic cardiomyopathy (HCM) conveys excess mortality when compared with the general population. Objective To compare the survival of patients with HCM with that of the general European population. Design, Setting,… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Nature Reviews Cardiology"
DOI: 10.1038/s41569-021-00636-y
Abstract: Valsartan is safe and effective in improving cardiac structure and function in patients with early-stage hypertrophic cardiomyopathy, according to results from the phase II VANISH trial. read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-020-80868-z
Abstract: Hypertrophic cardiomyopathy (HCM) is one of the most common hereditary heart diseases and can be classified into an obstructive (HOCM) and non-obstructive (HNCM) form. Major characteristics for HCM are the hypertrophy of cardiomyocytes and development… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Journal of cardiothoracic and vascular anesthesia"
DOI: 10.1053/j.jvca.2021.05.044
Abstract: OBJECTIVES Cleft-like indentations (CLIs) of the mitral valve (MV) are best assessed with three-dimensional (3D) transesophageal echocardiography (TEE). The present study examined the prevalence, characteristics, and surgical effect of MV CLIs in patients with hypertrophic… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehad028
Abstract: Abstract Aims Genetic hypertrophic cardiomyopathy (HCM) is caused by mutations in sarcomere protein-encoding genes (i.e. genotype-positive HCM). In an increasing number of patients, HCM occurs in the absence of a mutation (i.e. genotype-negative HCM). Mitochondrial… read more here.
Sign Up to like & get recommendations! 1
Published in 2018 at "Heart"
DOI: 10.1136/heartjnl-2017-312647
Abstract: Objective To identify electrocardiographic findings, especially deep Q and S waves in lead III, that differentiate athletes from patients with hypertrophic cardiomyopathy (HCM). Methods Digital ECGs of athletes and patients with HCM followed at the… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Heart"
DOI: 10.1136/heartjnl-2019-315818
Abstract: Objective Troponin and high signal intensity on T2-weighted (HighT2) cardiovascular magnetic resonance imaging (CMRi) are both markers of myocardial injury in hypertrophic cardiomyopathy (HCM). The interplay between exercise and disease development remains uncertain in HCM.… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Cardiology"
DOI: 10.1159/000471845
Abstract: Objectives: The relationship between a fragmented QRS (fQRS) and clinical outcomes in patients with hypertrophic cardiomyopathy (HCM) remains unclear. This study aimed to investigate the prognostic significance of fQRS in patients with HCM. Methods: Between… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "BMC Cardiovascular Disorders"
DOI: 10.1186/s12872-021-02373-z
Abstract: Objectives Our study aimed to determine the prevalence and prognosis of acute coronary syndrome with non-obstructive coronary artery (ACS-NOCA) in patients with hypertrophic cardiomyopathy (HCM). Methods and results We enrolledĀ a total of 200 consecutive patients… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "International Journal of General Medicine"
DOI: 10.2147/ijgm.s350673
Abstract: Background The aim of this study was to evaluate the capability of different magnetic resonance imaging (MRI) parameters for distinguishing between hypertrophic cardiomyopathy (HCM) and hypertensive heart disease (HHD). Methods Thirty-eight patients with HCM, 35… read more here.
Sign Up to like & get recommendations! 1
Published in 2023 at "Biomolecules"
DOI: 10.3390/biom13040665
Abstract: Hypertrophic cardiomyopathy (HCM) is a genetic condition determined by an altered collagen turnover of the extracellular matrix. Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) are abnormally released in patients with HCM. The purpose of this… read more here.